KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Liabilities and Shareholders Equity (2016 - 2026)

NovoCure's Liabilities and Shareholders Equity history spans 13 years, with the latest figure at $787.9 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 36.91% to $787.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.2 billion, a 14.71% decrease, with the full-year FY2025 number at $804.3 million, down 35.18% from a year prior.
  • Liabilities and Shareholders Equity hit $787.9 million in Q1 2026 for NovoCure, down from $804.3 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for NVCR hit a ceiling of $1.4 billion in Q3 2025 and a floor of $787.9 million in Q1 2026.
  • Historically, Liabilities and Shareholders Equity has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2022.
  • Biggest five-year swings in Liabilities and Shareholders Equity: grew 11.39% in 2025 and later tumbled 36.91% in 2026.
  • Tracing NVCR's Liabilities and Shareholders Equity over 5 years: stood at $1.2 billion in 2022, then fell by 3.82% to $1.1 billion in 2023, then rose by 8.26% to $1.2 billion in 2024, then plummeted by 35.18% to $804.3 million in 2025, then fell by 2.04% to $787.9 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for NVCR at $787.9 million in Q1 2026, $804.3 million in Q4 2025, and $1.4 billion in Q3 2025.